

Nivolumab CheckMate141

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**




### ADJUSTMENTS

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Nivolumab CheckMate141

### FINAL SCORE

**CURATIVE**




Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Head and neck cancer  
 Therapeutic Indication: As monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy  
 Experimental Arm: Nivolumab  
 Control Arm: Investigator choice (methotrexate or cetuximab or docetaxel)



